test
Published: 12 November
Interview
Is your AAV manufacturing process ready for producer cell lines?
Switching from transient transfection to a stable producer cell line promises lower costs, greater consistency, and easier scale-up.
This infographic distills a recent panel discussion with four experts in platform technologies, R&D, and regulatory affairs. Read to find out:
✓
When to make the switch, and how disruptive it is at each stage of development
✓
Why the cell line, not the plasmid, becomes your most critical starting material
✓
Whether a producer cell line switch triggers a clinical bridging study, and the three factors that shape how much data regulators expect
✓
Which assumptions about your downstream process may not hold
Explore the free interactive infographic below, or listen to the podcast here.